AstraZeneca Plc (AZN):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C15649)
◆英語タイトル:AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15649
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年3月
◆ページ数:88
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

AstraZeneca Plc (AZN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas including respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

AstraZeneca Plc Key Recent Developments

Mar 25,2019 AstraZeneca’s Forxiga garners EU approval in type 1 diabetes
Mar 25,2019 EU approves AstraZeneca’s drug for adjunct use in Type-1 diabetes
Mar 14,2019 AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting
Mar 14,2019 AstraZeneca: Appointment of M s. Sarah Wang as an additional director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
AstraZeneca Plc – Key Facts
AstraZeneca Plc – Key Employees
AstraZeneca Plc – Key Employee Biographies
AstraZeneca Plc – Major Products and Services
AstraZeneca Plc – History
AstraZeneca Plc – Company Statement
AstraZeneca Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
AstraZeneca Plc – Business Description
Business Segment: Biopharmaceuticals
Overview
Performance
Business Segment: Externalisation Revenue
Overview
Performance
Geographical Segment: Asia, Africa & Australasia
Target Markets
Performance
Geographical Segment: Continental Europe
Target Markets
Performance
Geographical Segment: The Americas
Target Markets
Performance
Geographical Segment: UK
Performance
R&D Overview
AstraZeneca Plc – Corporate Strategy
AstraZeneca Plc – SWOT Analysis
SWOT Analysis – Overview
AstraZeneca Plc – Strengths
AstraZeneca Plc – Weaknesses
AstraZeneca Plc – Opportunities
AstraZeneca Plc – Threats
AstraZeneca Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
AstraZeneca Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 25, 2019: AstraZeneca’s Forxiga garners EU approval in type 1 diabetes
Mar 25, 2019: EU approves AstraZeneca’s drug for adjunct use in Type-1 diabetes
Mar 14, 2019: AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting
Mar 14, 2019: AstraZeneca: Appointment of M s. Sarah Wang as an additional director
Mar 12, 2019: AstraZeneca, Seres Therapeutics to study new cancer therapy approach
Mar 11, 2019: AstraZeneca to Present New Cardiovascular Data on FARXIGA in Type 2 Diabetes At ACC 2019
Feb 27, 2019: Top pharma executives testify before US Senate over high prices
Feb 20, 2019: Study on regenerative angiogenesis in humans shows encouraging results
Feb 14, 2019: AstraZeneca announces full-year and Q4 2018 results
Feb 14, 2019: “MedImmune” brand to be retired as biologics integrate into AstraZeneca’s new R&D structure
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
AstraZeneca Plc, Key Facts
AstraZeneca Plc, Key Employees
AstraZeneca Plc, Key Employee Biographies
AstraZeneca Plc, Major Products and Services
AstraZeneca Plc, History
AstraZeneca Plc, Subsidiaries
AstraZeneca Plc, Joint Venture
AstraZeneca Plc, Key Competitors
AstraZeneca Plc, Ratios based on current share price
AstraZeneca Plc, Annual Ratios
AstraZeneca Plc, Annual Ratios (Cont...1)
AstraZeneca Plc, Annual Ratios (Cont...2)
AstraZeneca Plc, Interim Ratios
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
AstraZeneca Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
AstraZeneca Plc, Performance Chart (2014 - 2018)
AstraZeneca Plc, Ratio Charts
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ AstraZeneca Plc (AZN):企業の財務・戦略的SWOT分析(AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆